BiotechTube

Rivaroxaban + Placebo

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Symptomatic Superficial Vein Thrombosis

Conditions

Symptomatic Superficial Vein Thrombosis

Trial Timeline

Nov 11, 2014 → Dec 3, 2018

NCT ID
NCT02123524

About Rivaroxaban + Placebo

Rivaroxaban + Placebo is a phase 3 stage product being developed by Bayer for Symptomatic Superficial Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02123524. Target conditions include Symptomatic Superficial Vein Thrombosis.

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Superficial Vein Thrombosis were approved

Approved (3) Terminated (4) Active (9)
❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
🔄ISV-305Sun PharmaceuticalPhase 3
🔄rabeprazole sodium + PlaceboEisaiPhase 3
🔄Esomeprazole + Matching placeboAstraZenecaPhase 3
🔄Pasireotide + OctreotideNovartisPhase 3
✅valsartanNovartisApproved
🔄Apixaban + Standard of carePfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT04263038ApprovedRecruiting
NCT02555878Phase 3Completed
NCT02123524Phase 3Completed
NCT01877915Phase 3Completed

Competing Products

20 competing products in Symptomatic Superficial Vein Thrombosis

See all competitors
ProductCompanyStageHype Score
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ISV-305Sun PharmaceuticalPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Esomeprazole + Matching placeboAstraZenecaPhase 3
40
DFV890 + PlaceboNovartisPhase 2
35
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
35
Pasireotide + OctreotideNovartisPhase 3
40
TegaserodNovartisPhase 2
35
valsartanNovartisApproved
43
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Epoetin biosimilarPfizerPre-clinical
26
Apixaban + Standard of carePfizerPhase 3
40
Azithromycin plus chloroquinePfizerPhase 3
32
MavacamtenBristol Myers SquibbApproved
50
Aficamten + PlaceboSanofiPhase 3
44
Vandetanib 300 mgSanofiPre-clinical
26
REGN7508 + Acetylsalicylic Acid (ASA) + PlaceboRegeneron PharmaceuticalsPhase 3
47
Droxidopa capsules + Placebo capsulesLundbeckApproved
40